All News

DLE discoid lupus

ACR Promotes CME on Lupus Clinical Trials Racial Disparities

d ACR

The American College of Rheumatology (ACR) has released Continuing Medical Education (CME) for dermatologists and nephrologists to help them learn more about clinical trials for lupus patients in their respective treatment areas and the importance of getting more of their African American/Black p

Read Article
change-948024_640.jpg

Can You Withdraw Ixekizumab in Stable Axial Spondyloarthritis?

d Jack Cush, MD

Remission often invites consideration of drug withdrawal in patients with axial spondyloarthritis (axSpA).

Read Article
woman,doctor

Lack of Gender Equity in Academic Rheumatology

d Jack Cush, MD

Evidence on gender equity in academic rheumatology in Europe is currently limited. This knowledge gap has a direct effect on the ability of professional bodies to improve gender equity. To address this, EULAR designed a study using web-based surveys to collect information; here are the results.

Read Article
beer.jpg

Excessive Alcohol-Related Deaths in US Adults

d Jack Cush, MD

Alcohol consumption is a leading preventable cause of death in the U.S.  A JAMA cross-sectional study suggests that between 2015 and 2019, an estimated 1 in 8 total deaths among U.S. adults ages 20 to 64 were attributable to excessive alcohol use, including 1 in 5 deaths among adults ages 20 to 49. 

Read Article
warning, caution

EMA Crack Down on JAK Inhibitors

d Jack Cush, MD

The European Medicines Agency’s (EMA's) safety committee (PRAC) has issued a recommendation that the use of oral JAK inhibitors (tofacitinib, baricitinib, upadacitinib and filgotinib) be limited to certain at-risk patients unless no other suitable treatment alternatives are available.

Read Article
RheumNow #ACR22 reporter, Dr. Bella Mehta, will be covering SLE, gout and auto inflammatory topics this year. “I am looking forward to meeting collegues at ACR after 2 years!” -Dr. Mehta Follow @bella_mehta for real-time coverage during #ACR22. https://t.co/QQM2NrObPR
Dr. John Cush RheumNow ( View Tweet)
Follow our newest #ACR22 reporter, Dr. Julian Segan ( @JulianSegan)! “I am looking forward to is meeting all my rheumatology Twitter heroes!” Follow @RheumNow and our reporters for real-time #ACR22 coverage. https://t.co/7axxfOV6W8
Dr. John Cush RheumNow ( View Tweet)
China study of 109 w/ MPO+ vasculitis (MPO-AAV), 23 w/ anti-GBM & 20 Double positive (MPO+ GBM+) (DPP) pts showed DPP pts were older(p=0.007), higher creatinine & lower GFR, & had multi-organ damage (cardiac) outside the kidney https://t.co/3aGPnfVDrs https://t.co/E557RLogCE

Links:

Dr. John Cush RheumNow ( View Tweet)
Drug-induced Hepatotoxicity - many Rheum drugs on the list: Tylenol, azathioprine, allopurinol, cyclosporine, dapsone, gold, MTX, 6-MP, NSAIDs, ASA, SSZ, Minocin... https://t.co/wuoVrDgesq https://t.co/SAWPdsQ6I3

Links:

Dr. John Cush RheumNow ( View Tweet)
What is RheumNow ACR reporter, Dr. Rachel Tate, most looking forward to at #ACR22? “Onsite, in person learning!” Follow @uptoTate for real-time #ACR22 coverage! https://t.co/nMw015dpdl
Dr. John Cush RheumNow ( View Tweet)
Opportunistic infections in #PsA pts on b/tsDMARDS is low. Metanalysis 47 studies, 17,197 pts - OI risk by MOA:1) JAK inhib 2.72%, 2) anti-IL-17 1.18%, 3) anti-IL-23 0.24% , 4) TNFi 0.01%. H. zoster w/ JAKi= 2.53% & Candida risk w/ IL-17=0.97% https://t.co/a5fJcWTxnL https://t.co/GQKoV7Hg6m

Links:

Dr. John Cush RheumNow ( View Tweet)
GSK announced they will halt development of Otilimab (anti-GM-CSF mAb) to treat #RA; decisioin based on negative results from phase 3 ContRAst-3 study, that failed to meet ACR20 primary endpoint in RA pts who failed bDMARDs or JAKi https://t.co/cDqcYKOjSa https://t.co/7rB4TYsWnZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Infection: a Leading Cause of Death in Lupus Analysis of a national database of hospital discharges from Spain shows that infections accounted for 25% of lupus deaths, making infection the most common cause of death in SLE. https://t.co/uTQd3afwxR https://t.co/okBHWel62d

Links:

Dr. John Cush RheumNow ( View Tweet)
What's Dr. Dao looking most forward to at #ACR2022? "To covering the meeting and learning of new developments in rheumatology. I am also excited to mentor my medical student on her first ACR meeting where she will be presenting a poster on social media in medical education.' https://t.co/27PcSmJUZe
Dr. John Cush RheumNow ( View Tweet)
Join Dr. Jack Cush and Dr. Arthur Kavanaugh as they discuss, dissect and deliberate about data presented at the #ACR2022 meeting in Philadelphia. https://t.co/yCMStA8yQm https://t.co/myS0sT9BMq

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow #ACR2022 Reporter Spotlight: Dr. Richard Conway What are you most looking forward to this year at ACR? Dr. Conway: "I'm looking forward to experiencing the enhanced virtual offering this year." Follow him at @RichardPAConway for more ACR RheumNow coverage! https://t.co/xwl8Jqn1Yf
Dr. John Cush RheumNow ( View Tweet)
Chest CT Airway Dz compared betw GPA (n26) & relapsing polychondritis (n19). Subglottic involvement favors GPA (OR 28.6) & Extensive airway Dz favor of RP (GP OR 0.02). Lesser RP assoc w/ Posterior tracheal sparing & tracheal calcifications. https://t.co/TaaEjpPm76 https://t.co/mwljLYIymH

Links:

Dr. John Cush RheumNow ( View Tweet)
Increasing Risk of Lupus Nephritis A population based study shows that LN in the US has increased in the last four decades and that LN patients have poorer outcomes with high rates of ESRD and mortality rates 6x that of the general population. https://t.co/aBSUP9ExTh https://t.co/RfgSH0wmOu

Links:

Dr. John Cush RheumNow ( View Tweet)
Update to Axial Spondyloarthritis Guidance EULAR and the Assessment of SpondyloArthritis International Society (ASAS) has updated their guidance on axial spondyloarthritis (axSpA) management. https://t.co/iAUXrVp1P3 https://t.co/bHwjI6xJUq

Links:

Dr. John Cush RheumNow ( View Tweet)
New ACR/EULAR Guideline Expands RA Remission Definition Newly released guidance for defining remission in RA is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes. https://t.co/ZZN3kAGW8F https://t.co/iaYUvxYHMq

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×